The Medicare demonstration known as the Bridge program is an 18-month pilot that offers reduced-cost access to selected GLP-1 medications for weight loss and management. To participate, beneficiaries must be enrolled in Medicare Part D. The program broadly allows beneficiaries with a body mass index (BMI) of 35 or higher to qualify. People with BMI between 27 and 34 may qualify if they have specified comorbid conditions such as prediabetes or cardiovascular disease.
Although Part D enrollment is required, the Bridge’s enrollment and prior authorization process is handled outside the beneficiary’s insurer through a contractor operating on behalf of the Centers for Medicare & Medicaid Services (CMS).
Instead of routing prior authorization requests through a beneficiary’s Part D plan, the Bridge uses a separate submission system managed by a CMS contractor. CMS reported that, in the demonstration’s first weeks, most prior authorization requests were completed in under 12 hours. That rapid processing has enabled thousands of eligible beneficiaries to access GLP-1 medications for weight loss at participating pharmacies nationwide.
The demonstration includes three GLP-1 therapies prescribed for weight loss and management: Wegovy, the KwikPen formulation of Zepbound, and the oral agent Foundayo. Under Bridge, eligible beneficiaries can obtain one of those medications for a $50 monthly cost during the pilot period when the drug is being used solely for weight loss.
A key limitation of the Bridge program is that the $50 monthly price applies only when a GLP-1 is used solely for weight loss. Beneficiaries who have medical conditions for which the Food and Drug Administration has approved GLP-1s as a treatment — such as Type 2 diabetes or moderate-to-severe obstructive sleep apnea — are routed back to their Medicare Part D plans rather than receiving the Bridge subsidy. As a result, patients who might have the greatest clinical need can be excluded from the lower-cost option if they have an FDA-recognized indication for a GLP-1.
The distinction in permitted use has created confusion and frustration among some applicants, in part because notification of denial has not always specified the precise reason for rejection.
CMS has not released an official federal estimate of the demonstration’s total cost. KFF analysts have estimated that roughly 3.8 million Medicare beneficiaries met the eligibility criteria in 2023. Using uptake and retention scenarios, KFF estimated that if one-quarter of those eligible enroll and remain on treatment for the full 18 months, costs could be about $3.3 billion; if three-quarters enroll and persist, costs could reach about $10 billion. Expanding the program to include the additional estimated 5.9 million beneficiaries already eligible for GLP-1 coverage under Part D would add billions more to the potential cost.
How many beneficiaries ultimately enroll, and how long they remain on therapy during the demonstration, will substantially influence Medicare’s outlays.
The article profiles a 68-year-old beneficiary, Jeff La Marca, who sought coverage for Zepbound but was denied participation in Bridge. La Marca reported a BMI of 42, a history of quadruple coronary artery bypass surgery, prediabetes, and severe obstructive sleep apnea. The sleep apnea diagnosis is one of the conditions that CMS and program rules treat as an FDA-approved indication for GLP-1 therapy; that contributed to his routing back to Part D rather than approval for the $50 Bridge price. La Marca said the denial notice did not state the reason.
Patients like La Marca may technically have Part D coverage for a GLP-1 but still face substantial monthly copays when obtaining the drug through their Part D plan. Clinicians and patients have reported copays commonly ranging from a couple of hundred dollars to several hundred dollars per month under Part D in many cases.
Proponents of the Bridge program describe it as aimed at people who cannot obtain GLP-1 coverage through Part D but would benefit from the drugs for weight loss. Critics, including some clinicians, say the demonstration leaves behind some of the sickest beneficiaries by excluding those with FDA-approved indications from the $50 subsidy, effectively shifting them back to Part D where cost sharing is often higher and additional utilization management — prior authorization and step therapy — can delay access.
Research cited by the article indicates that most Part D plans require prior authorization for GLP-1s and that beneficiaries have faced increases in out-of-pocket costs. Industry groups and plan representatives have pointed to drugmakers’ list prices as a major driver of high costs for insurers and beneficiaries.
The Bridge demonstration’s short-term outcomes, administrative performance, and financial impact will determine whether it is expanded, tightened, or modified. For now, some beneficiaries with qualifying comorbidities and documented clinical need remain unable to access the $50 Bridge price and continue to confront potentially unaffordable copays under Part D.
The Medicare GLP-1 Bridge pilot creates a lower-cost pathway to selected weight-loss GLP-1 therapies for many beneficiaries but explicitly excludes people with medical conditions for which GLP-1s are FDA-approved treatments. That exclusion has left an estimated millions of beneficiaries either ineligible for the subsidy or reliant on Part D coverage with higher out-of-pocket costs. CMS processing times in the program’s early weeks were reported to be rapid, but the program’s long-term fiscal and access consequences depend on enrollments, retention, and possible policy changes.